Rockefeller Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Rockefeller Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$166K	Sell	17,854 -200	-1%	-$1.74K	﹤0.01%	2602
2025 Q4	$135K	Buy	18,054 +17,929	+14,343%	+$182K	﹤0.01%	2567
2025 Q3	$1.09K	Buy	+125	New	+$747	﹤0.01%	4179
2021 Q4	–	Sell	-1,070	Closed	-$28K	–	3829
2021 Q3	$28K	Sell	1,070 -130	-11%	-$3.71K	﹤0.01%	2428
2021 Q2	$28K	Sell	1,200 -4,735	-80%	-$145K	﹤0.01%	2328
2021 Q1	$257K	Buy	+5,935	New	+$263K	﹤0.01%	1253

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rockefeller Capital Management's FDMT Position: Q1 2026 in Review

Rockefeller Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 1.1% in Q1 2026, selling an estimated $1.74K and leaving 17,854 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #2602.

Rockefeller Capital Management first reported a position in FDMT in Q1 2021 and has held it in 6 quarters since. The position peaked at $257K in Q1 2021. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Rockefeller Capital Management held 17,854 shares of 4D Molecular Therapeutics worth $166K as of Q1 2026.
Rockefeller Capital Management sold 200 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.74K.
4D Molecular Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2602 holding.
Rockefeller Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 6 quarters since.
Rockefeller Capital Management's 4D Molecular Therapeutics position peaked at $257K in Q1 2021.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.